TCIM
MACK

TIAA CREF Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

TIAA CREF Investment Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$2.8M Hold
511,523
– – ﹤0.01% 1811
2018
Q4 		$1.55M Hold
511,523
– – ﹤0.01% 2100
2018
Q3 		$2.15M Hold
511,523
– – ﹤0.01% 2088
2018
Q2 		$1.98M Sell
511,523
-186,105
-27% -$1.24M ﹤0.01% 2179
2018
Q1 		$4.42M Sell
697,628
-3,138
-0.4% -$26K ﹤0.01% 1630
2017
Q4 		$5.65M Sell
700,766
-13,925
-2% -$130K ﹤0.01% 1534
2017
Q3 		$8.18M Buy
714,691
+7,483
+1% +$78.7K 0.01% 1277
2017
Q2 		$6.9M Sell
707,208
-104,340
-13% -$2.13M ﹤0.01% 1375
2017
Q1 		$19.7M Sell
811,548
-2,349
-0.3% -$58.8K 0.01% 757
2016
Q4 		$26.1M Buy
813,897
+75,855
+10% +$3.23M 0.02% 656
2016
Q3 		$36.9M Buy
738,042
+32,248
+5% +$1.34M 0.02% 539
2016
Q2 		$29.9M Buy
705,794
+11,129
+2% +$606K 0.02% 581
2016
Q1 		$45.7M Buy
694,665
+47,918
+7% +$2.5M 0.04% 459
2015
Q4 		$40.2M Buy
646,747
+66,586
+11% +$4.68M 0.03% 529
2015
Q3 		$38.8M Buy
580,161
+185,729
+47% +$15.2M 0.03% 518
2015
Q2 		$38.4M Buy
394,432
+66,843
+20% +$6.36M 0.03% 560
2015
Q1 		$30.6M Buy
327,589
+272,076
+490% +$23.2M 0.02% 634
2014
Q4 		$4.94M Sell
55,513
-2,811
-5% -$205K ﹤0.01% 1635
2014
Q3 		$4.03M Sell
58,324
-1,556
-3% -$83.1K ﹤0.01% 1767
2014
Q2 		$3.43M Buy
59,880
+1,153
+2% +$58.5K ﹤0.01% 1944
2014
Q1 		$2.33M Buy
58,727
+2,227
+4% +$95.3K ﹤0.01% 2148
2013
Q4 		$2.37M Sell
56,500
-1,766
-3% -$51.2K ﹤0.01% 2149
2013
Q3 		$1.74M Buy
58,266
+11,399
+24% +$399K ﹤0.01% 2302
2013
Q2 		$2.48M Buy
+46,867
New +$2.05M ﹤0.01% 2028

Other funds holding MACK

NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
2L
22NW LP Seattle, Washington $105M AUM 38.33% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
WSL
Western Standard LLC Los Angeles, California $295M AUM 40.98% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $292M AUM 36.12% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

TIAA CREF Investment Management's MACK Position: Q1 2019 in Review

TIAA CREF Investment Management held its Merrimack Pharmaceuticals, Inc. (MACK) position steady in Q1 2019 at 511,523 shares worth $2.8M. The position accounts for ﹤0.01% of the portfolio, ranked #1811.

TIAA CREF Investment Management first reported a position in MACK in Q2 2013 and has held it in 24 quarters since. The position peaked at $45.7M in Q1 2016. 54 funds tracked by Wall St. Rank hold MACK as of Q1 2019.

  • TIAA CREF Investment Management held 511,523 shares of Merrimack Pharmaceuticals, Inc. worth $2.8M as of Q1 2019.
  • TIAA CREF Investment Management left its Merrimack Pharmaceuticals, Inc. share count unchanged in Q1 2019.
  • Merrimack Pharmaceuticals, Inc. made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #1811 holding.
  • TIAA CREF Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2013 and has held it in 24 quarters since.
  • TIAA CREF Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $45.7M in Q1 2016.
  • 54 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.